САЩ - английски - NLM (National Library of Medicine)

cbschem limited - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

САЩ - английски - NLM (National Library of Medicine)

mutual pharmaceutical company - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate (unii: h527kap6l5) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - tablet - 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful

САЩ - английски - NLM (National Library of Medicine)

rebel distributors corp - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 1000 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

САЩ - английски - NLM (National Library of Medicine)

abbvie inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. - niaspan in combination with a bile acid binding resin is indicated to reduce elevated tc an

САЩ - английски - NLM (National Library of Medicine)

dispensing solutions, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 1000 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

САЩ - английски - NLM (National Library of Medicine)

dispensing solutions, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

САЩ - английски - NLM (National Library of Medicine)

physicians total care, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

САЩ - английски - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) - rylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (all) and lymphoblastic lymphoma (lbl) in adult and pediatric patients 1 month or older who have developed hypersensitivity to e. coli -derived asparaginase. rylaze is contraindicated in patients with: risk summary based on findings from animal reproduction studies, rylaze can cause fetal harm when administered to a pregnant woman. there are no available data on rylaze use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproductive and developmental toxicity studies, intramuscular administration of asparaginase erwinia chrysanthemi to pregnant rats and rabbits during organogenesis resulted in structural abnormalities and embryo-fetal mortality (see data ) at exposures below those in patients at the recommended human dose. advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. data animal data animal reproductive and developmental toxicity studies have not been conducted with rylaze. in embryofetal development studies, asparaginase erwinia chrysanthemi was administered intramuscularly every other day during the period of organogenesis to pregnant rats (at 3, 6, or 12 mg/m2 ) and rabbits (at 0.12, 0.30, or 0.48 mg/m2 ). in rats given 12 mg/m2 (approximately 0.48 times the maximum recommended human dose), maternal toxicity of decreased body weight gain was observed, as was a fetal finding of increased incidence of partially undescended thymic tissue. in rabbits, maternal toxicity consisting of decreased body weight was observed at 0.48 mg/m2 (approximately 0.02 times the maximum recommended human dose). increased post-implantation loss, a decrease in the number of live fetuses, and gross abnormalities (e.g., absent kidney, absent accessory lung lobe, additional subclavian artery, and delayed ossification) were observed at doses of ≥ 0.12 mg/m2 (approximately 0.005 times the maximum recommended human dose). risk summary there are no data on the presence of asparaginase erwinia chrysanthemi (recombinant)-rywn in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with rylaze and for 1 week after the last dose. rylaze can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . pregnancy testing pregnancy testing is recommended in females of reproductive potential prior to initiating rylaze. contraception advise females of reproductive potential to use effective non-hormonal contraceptive methods during treatment with rylaze and for 3 months after the last dose. the safety and effectiveness of rylaze in the treatment of all and lbl have been established in pediatric patients 1 month to < 17 years who have developed hypersensitivity to a long-acting e. coli -derived asparaginase. use of rylaze in these age groups is supported by evidence from an adequate and well-controlled study in adults and pediatric patients. the trial included 139 pediatric patients, including 2 infants (1 month to < 2 years), 99 children (2 years to < 12 years old), and 38 adolescents (12 years to < 17 years old). there were no clinically meaningful differences in safety or nadir serum asparaginase activity across age groups. the safety and effectiveness of rylaze have not been established in pediatric patients younger than 1 month of age. clinical studies of rylaze did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

the royal children's hospital - monosodium aspartate, quantity: 1.4 mmol/ml - injection, concentrated - excipient ingredients: water for injections - substrate for organ perfusion.

САЩ - английски - NLM (National Library of Medicine)

ax pharmaceutical corp - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -